About
Research in Professor Lu-Gang Yu's laboratory is focused on the functional significance and molecular actions of cellular glycosylation and carbohydrate-binding proteins (lectins), in particular galectins, in cancer development, progression and metastasis. Research in his laboratory has a strong element in translational development of galectin-targeted novel therapeutics for cancer treatment. The discovery of several novel classes of pre-clinical and clinical galectin-3 inhibitors in his laboratory led to the University spun-out a biotech company GALYTX LTD (www.galytx.com) to develop galectin-3-targeted novel therapeutic drugs for treatment of cancer and other galectin-3-mediated pathologies. Research in his laboratory has been supported by various national and international funding agencies including MRC, CRUK, BBSRC, Wellcome Trust, Northwest Cancer Research Fund, Royal Society, American Institute for Cancer Research, World Cancer Research Fund, and Mizutani Foundation for Glycosciences.